<DOC>
	<DOCNO>NCT00855452</DOCNO>
	<brief_summary>The present protocol phase 2 study design investigate potential application allogeneic cell-mediated immunotherapy metastatic solid tumor , similarly well establish graft versus leukemia ( GVL ) effect , patient metastatic solid tumor resistant conventional treatment modality . Patients eligible participate treatment program base systemic administration mismatch lymphocyte activate vitro rIL-2 ( LAK ) follow rIL-2 inoculation vivo . This treatment aim induce anti-tumor effect mediate efficient kill activity rIL-2 activate cell . Prior cell infusion patient receive condition treatment low dose Cyclophosphamide ( Cyc ) Fludarabine 2 injection low dose alpha interferon . Cell therapy combine specific anti-tumor monoclonal antibody available specific disease . Further activation anti-tumor activity alloreactive donor T cell natural killer ( NK ) cell accomplish vivo inoculation rIL-2 , aim enhance anti-cancer potential donor-derived effector cell . Patients receive one - three cycle cell therapy , long sign Graft- versus - Host - disease ( GVHD ) malignant disease control .</brief_summary>
	<brief_title>Activated Allogeneic Lymphocytes Induction Graft Versus Tumor Effect Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<criteria>Consenting patient ( age 1270 ) eligible participation study involve antitumor immunotherapy provide follow criterion meet : 1 . Evidence cancer expect cure conventional modality : Pediatric patient : Chemotherapyresistant neuroblastoma stage 4 &amp; sarcoma . Adult patient : Metastatic breast cancer , malignant melanoma , renal cell cancer select case ovary cancer , gastrointestinal cancer , smallcell nonsmall cell lung cancer nonbulky metastatic disease , metastatic prostate cancer . 2 . Patients measurable disease evaluable response anticipate life expectancy &gt; 3 month . 3 . Patients must &gt; 2 week anticancer potentially immunosuppressive treatment . 4 . Adequate ambulatory performance status ( Karnofsky &gt; 80 % ; ECOG 01 ) enable outpatient treatment ( see Appendix 1 ) . 5 . Compliant cooperative patient anticipate evaluable response accord investigator 's assessment . 6 . HLAnoncompatible ( partial match mismatch ) donor available . Patients exclude participation study follow criterion meet : 1 . Any criteria met . 2 . Patients significant history current evidence potentially severe cardiovascular disease . 3 . Hepatic and/or renal failure . 4 . Abnormal PT PTT . 5 . Patients abnormal hemogram ( PMN &lt; 1.0x109/L ; HB &lt; 10 ; Plts &lt; 50x109/L ) 6 . Evidence serious active infection require antibiotic therapy . 7 . Evidence active disease require steroid cytotoxic therapy . 8 . Pregnancy . 9 . Contraindication donation due donor disease : HIV1 ; HBsAg positivity .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>GVL</keyword>
	<keyword>rIL-2 ( LAK )</keyword>
	<keyword>GVHD</keyword>
	<keyword>MST</keyword>
	<keyword>alloCT</keyword>
	<keyword>alloBMT</keyword>
</DOC>